Viking Therapeutics Stock Drops 0.58% as Obesity Drug Pipeline Advances and Trading Volume Ranks 418th

Viking Therapeutics (VKTX) closed 0.58% lower on August 25, 2025, with a trading volume of $220 million, ranking 418th in daily equity activity. The stock’s recent performance has been influenced by its advancing obesity drug pipeline. The company announced a manufacturing agreement with CordenPharma to support commercialization of VK2735, a key step toward potential market entry.

Positive momentum came from clinical progress: a Phase 2 VENTURE trial showed the oral tablet formulation of VK2735 met its primary endpoint in obesity patients. Additionally, the Phase 3 VK2735 trial is nearing completion, signaling a critical inflection point for the company’s development timeline. Analysts note these developments could strengthen Viking’s position in the competitive weight-loss therapeutics sector.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The 1-day return was 0.98%, with a total return of 31.52% over 365 days. This indicates the strategy captured some short-term momentum but was subject to market fluctuations. It performed best in June 2023, with returns of 7.02%, and worst in September 2022, with a return of -4.65%. Overall, the strategy showed volatility but a positive trend, making it suitable for traders looking for short-term opportunities.